Teva Pharmaceutical Industries Beats Analyst Estimates on EPS

Before you go, we thought you'd like these...
Before you go close icon

Teva Pharmaceutical Industries (NAS: TEVA) reported earnings on May 9. Here are the numbers you need to know.

The 10-second takeaway
For the quarter ended March 31 (Q1), Teva Pharmaceutical Industries missed estimates on revenue and beat slightly on earnings per share.

Compared to the prior-year quarter, revenue increased significantly and GAAP earnings per share increased significantly.


Margins shrank across the board.

Revenue details
Teva Pharmaceutical Industries chalked up revenue of $5.10 billion. The 20 analysts polled by S&P Capital IQ expected net sales of $5.51 billion on the same basis. GAAP reported sales were 25% higher than the prior-year quarter's $4.08 billion.

anImage

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
EPS came in at $1.47. The 24 earnings estimates compiled by S&P Capital IQ averaged $1.44 per share. GAAP EPS of $0.97 for Q1 were 15% higher than the prior-year quarter's $0.84 per share.

anImage

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin details
For the quarter, gross margin was 51.1%, 280 basis points worse than the prior-year quarter. Operating margin was 21.1%, 110 basis points worse than the prior-year quarter. Net margin was 16.8%, 190 basis points worse than the prior-year quarter.

Looking ahead
Next quarter's average estimate for revenue is $5.41 billion. On the bottom line, the average EPS estimate is $1.35.

Next year's average estimate for revenue is $21.92 billion. The average EPS estimate is $5.61.

Investor sentiment
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 2,475 members out of 2,543 rating the stock outperform, and 68 members rating it underperform. Among 550 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 545 give Teva Pharmaceutical Industries a green thumbs-up, and five give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Teva Pharmaceutical Industries is outperform, with an average price target of $53.48.

Can your portfolio provide you with enough income to last through retirement? You'll need more than Teva Pharmaceutical Industries. Learn how to maximize your investment income in our free report: "Secure Your Future With 9 Rock-Solid Dividend Stocks." Click here for instant access to this free report.

  • Add Teva Pharmaceutical Industries to My Watchlist.

At the time this article was published

Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

Want more news like this?

Sign up for Finance Report by AOL and get everything from business news to personal finance tips delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.

From Our Partners